Stay updated on Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.

Latest updates to the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page
- Check6 days agoChange DetectedAdded a dedicated Locations section with New York as a site; the old New York Locations header was removed and the page updated to revision v3.3.3.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check42 days agoChange DetectedThe page no longer displays the government funding status notice. All study details, locations, and eligibility criteria remain unchanged.SummaryDifference0.4%

- Check56 days agoChange DetectedNo significant changes detected between the previous and current page versions. The content and study details appear unchanged aside from minor layout tweaks.SummaryDifference0.4%

- Check85 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference4%

- Check92 days agoChange DetectedUpgrade applied: version updated from v3.0.2 to v3.1.0. No other substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Azacitidine and Pembrolizumab in Pancreatic Cancer Clinical Trial page.